Why is Collegium Pharmaceutical stock tumbling today?
Collegium Pharmaceutical shares fell about 13% in pre-open trading after it reported Q2 2026 results and cut full-year revenue guidance. Net revenues were $199.9M, up 6.3% but below analysts’ ~$201.2M-$201.4M. Adjusted EPS was $1.92 and adjusted EBITDA $113.8M. The pain portfolio faced generic competition, while JORNAY PM rose 41% to $46.1M and AZSTARYS added $12.9M.
How this was made
The 30-second read
Why it matters
Investors appear to be trading the guidance cut and pain-portfolio generic-competition headwinds more than the adjusted earnings beats, pushing the stock toward its 52-week low.
Market read
A guidance reset plus a top-line miss is the immediate catalyst, making this a direct earnings-and-guidance trading event rather than a macro story.
What to watch
The article notes AZSTARYS contribution post-acquisition; traders may re-rate the stock if investors conclude the pain-portfolio headwinds are temporary and acquisition synergies offset them.
Background
Collegium reported Q2 2026 results before the open and simultaneously trimmed full-year revenue guidance.
Ticker impact
Collegium Pharmaceutical shares fell 13.2% pre-open after Q2 results and a full-year revenue outlook cut, despite EPS and EBITDA beats.
Near-term bias remains bearish while the market digests the lowered full-year revenue midpoint and ongoing generic-competition headwinds.
The article cites a top-line miss versus consensus and a full-year revenue guidance midpoint about 3.4% below Street estimates, which typically outweighs adjusted EPS/EBITDA beats.
Market effects
Highlights ongoing pricing pressure from generics in specialty pain drugs, reinforcing caution on similar pain-portfolio revenue durability.
No specific regional spillover beyond a modest NASDAQ red backdrop.
Limited; the catalyst is company-specific guidance and portfolio performance.
Counterpoint
The quarter showed adjusted EPS and EBITDA beats and strong JORNAY PM growth, so the guidance cut may reflect timing or conservatism rather than a structural demand collapse.
Key entities
- companyCollegium Pharmaceutical
Specialty biopharmaceutical company whose Q2 results and full-year revenue guidance cut drove a sharp pre-open decline.
- productBELBUCA
Pain franchise product referenced as part of the portfolio facing generic-competition headwinds.
- productXtampza ER
Pain franchise product referenced as part of the portfolio facing generic-competition headwinds.
- productNucynta franchise
Pain franchise referenced as part of the portfolio facing generic-competition headwinds.
- productJORNAY PM
Pain product cited as rising 41% year-over-year to $46.1 million.
